Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device

Left ventricular assist device (LVAD) technology has improved the survival of advanced heart failure patients. However, readmission rates following LVAD implantation remain high and are an unsolved matter. Currently, gastrointestinal bleeding is one of the major causes of readmission and has recentl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation journal : official journal of the Japanese Circulation Society Ročník 82; číslo 12; s. 2931
Hlavní autoři: Imamura, Teruhiko, Kinugawa, Koichiro, Uriel, Nir
Médium: Journal Article
Jazyk:angličtina
Vydáno: Japan 24.11.2018
Témata:
Angiogenesis
HeartMate
Left ventricular assist device (LVAD)
Omega-3
Hemocompatibility
ISSN:1347-4820, 1347-4820
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Left ventricular assist device (LVAD) technology has improved the survival of advanced heart failure patients. However, readmission rates following LVAD implantation remain high and are an unsolved matter. Currently, gastrointestinal bleeding is one of the major causes of readmission and has recently been demonstrated to mainly result from increased angiogenesis. In addition to the conventional therapeutic strategies, including a reduction in antiplatelet and anticoagulation therapies and blood products administration, several therapeutic tools have recently been proposed: octreotide, thalidomide, hemodynamic optimization by the ramp test, and fish oil therapy. This review will update the therapeutic strategy for gastrointestinal bleeding in LVAD patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1347-4820
1347-4820
DOI:10.1253/circj.CJ-18-0883